Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Clinical Oncology

• Publication date

  2006-04-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2005.04.2838PMID 16622259
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Skeletal muscle wasting in tumor-bearing rats is associated with MyoD down-regulation.

  2005cited by this paper
• NF-κB: linking inflammation and immunity to cancer development and progression

  2005cited by this paper
• NF-kappaB: linking inflammation and immunity to cancer development and progression.

  2005cited by this paper
• Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer.

  2004cited by this paper
• NF-kappaB functions as a tumour promoter in inflammation-associated cancer.

  2004cited by this paper
• IKK Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer

  2004cited by this paper
• NF-κB functions as a tumour promoter in inflammation-associated cancer

  2004cited by this paper
• Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.

  2003cited by this paper
• Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349).

  2003cited by this paper
• Inhibition of NF-κB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin

  2002cited by this paper
• Tumour necrosis factor-alpha mediates tumour promotion via a PKC alpha- and AP-1-dependent pathway.

  2002cited by this paper
• Tumour necrosis factor-α mediates tumour promotion via a PKCα- and AP-1-dependent pathway

  2002cited by this paper
• CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-κB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells

  2001cited by this paper
• NF-kappa B-mediated chemoresistance in breast cancer cells.

  2001cited by this paper
• NF-κB–mediated chemoresistance in breast cancer cells

  2001cited by this paper
• Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset

  2001cited by this paper
• Inhibition of NF-κB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin

  2001cited by this paper
• Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset.

  2001cited by this paper
• Signal transduction by tumor necrosis factor and its relatives.

  2001cited by this paper
• Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.

  2001cited by this paper
• Upregulation of Bcl-x and Bfl-1 as a potential mechanism of chemoresistance, which can be overcome by NF-κB inhibition

  2000cited by this paper
• NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia.

  2000cited by this paper
• Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group.

  2000cited by this paper
• Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothe cin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-kappaB activation.

  2000cited by this paper
• Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.

  2000cited by this paper
• Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab.

  2000cited by this paper
• Docetaxel administered on a weekly basis for metastatic breast cancer.

  2000cited by this paper
• Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis

  1999cited by this paper
• Systemic administration of the NF-κB inhibitor curcumin stimulates muscle regeneration after traumatic injury.

  1999cited by this paper
• A new model of cancer cachexia: contribution of the ubiquitin-proteasome pathway.

  1999cited by this paper
• Evaluation of Palliative Endpoints in Oncology Clinical Trials.

  1999cited by this paper
• On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease

  1999cited by this paper
• Calpain 3 deficiency is associated with myonuclear apoptosis and profound perturbation of the IκBα/NF-κB pathway in limb-girdle muscular dystrophy type 2A

  1999cited by this paper
• NF- kappa B and chemoresistance: could NF- kappa B be an antitumor target?

  1999cited by this paper
• Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response.

  1999cited by this paper
• Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis.

  1999cited by this paper
• NF- kappa B and chemoresistance: potentiation of cancer drugs via inhibition of NF- kappa B.

  1999cited by this paper
• Activators and target genes of Rel/NF-kappaB transcription factors.

  1999cited by this paper
• A new model of cancer cachexia: contribution of the ubiquitin-proteasome pathway.

  1999cited by this paper
• Infliximab for the treatment of fistulas in patients with Crohn's disease.

  1999cited by this paper
• Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB

  1999cited by this paper
• Intratumoral injection of oligonucleotides to the NFκB binding site inhibits cachexia in a mouse tumor model

  1999cited by this paper
• Calpain 3 deficiency is associated with myonuclear apoptosis and profound perturbation of the IkappaB alpha/NF-kappaB pathway in limb-girdle muscular dystrophy type 2A.

  1999cited by this paper
• Activators and target genes of Rel/NF-κB transcription factors

  1999cited by this paper
• Clinical applications of TNF-alpha in cancer.

  1998cited by this paper
• Measurement of Fatigue in Cancer Patients: Development and Validation of the Fatigue Symptom Inventory

  1998cited by this paper
• Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B.

  1998cited by this paper
• Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.

  1998cited by this paper
• Clinical applications of TNF-α in cancer

  1998cited by this paper
• Prevention of adenocarcinoma colon 26-induced cachexia by interleukin 10 gene transfer.

  1997cited by this paper
• Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors.

  1997cited by this paper
• Muscle wasting and dedifferentiation induced by oxidative stress in a murine model of cachexia is prevented by inhibitors of nitric oxide synthesis and antioxidants.

  1996cited by this paper
• The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death.

  1994cited by this paper
• Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte).

  1993cited by this paper
• Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion.

  1993cited by this paper
• The role of cytokines in muscle wasting: Its relation with cancer cachexia

  1992cited by this paper
• High incidence of coagualopathy in phase II studies of recombinant tumor necrosis factor in advanced pancreatic and gastric cancers.

  1992cited by this paper
• Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis.

  1990cited by this paper
• Predicting the course of Gompertzian growth

  1976cited by this paper

• Chronic Fatigue in Cancer Survivorship: Psychiatry Versus Oncology or Psychiatry with Oncology?

  2025cites this paper
• Comorbid symptoms in cancer patients and caring for the caregiver

  2025cites this paper
• Predictive risk model of mild cognitive impairment in patients with malignant haematological diseases after haematopoietic stem cell transplantation

  2025cites this paper
• Determining the Selenium Level in Patients With Cancer‐Related Fatigue (2023)

  2025cites this paper
• Inflammation and cancer: molecular mechanisms and clinical consequences

  2025cites this paper
• Immune System Disorder and Cancer-Associated Cachexia

  2024cites this paper
• Neurophysiology and Molecular Basis of Cognitive Behavioral Therapy for Patients with Insomnia: Implications for Non-Pharmacological Approaches.

  2024cites this paper
• A computational account of joint SSRI and anti-inflammatory treatment

  2023cites this paper
• Symptom clusters in palliative-stage cancer correlate with proinflammatory cytokine cluster.

  2023cites this paper
• SCEL regulates switches between pro-survival and apoptosis of the TNF-α/TNFR1/NF-κB/c-FLIP axis to control lung colonization of triple negative breast cancer

  2023cites this paper
• Associations of inflammation with neuropsychological symptom cluster in patients with Head and neck cancer: A longitudinal study

  2023cites this paper
• Molecular mechanisms of tumour necrosis factor signalling via TNF receptor 1 and TNF receptor 2 in the tumour microenvironment.

  2023cites this paper
• Cancer cachexia as a multiorgan failure: Reconstruction of the crime scene

  2022cites this paper
• Pre-treatment levels of inflammatory markers and chemotherapy completion rates in patients with early-stage breast cancer

  2022cites this paper
• Emerging signaling mediators in the anorexia-cachexia syndrome of cancer.

  2022cites this paper
• Impact of radiation therapy on fatigue at 1 year in breast cancer survivors in the prospective multicentre CANcer TOxicity cohort.

  2022cites this paper
• Drug repositioning for esophageal squamous cell carcinoma

  2022cites this paper
• The Brain-Gut Axis: Psychological Functioning and Inflammatory Bowel Diseases

  2021cites this paper
• MRI-Determined Psoas Muscle Fat Infiltration Correlates with Severity of Weight Loss during Cancer Cachexia

  2021cites this paper
• Targeting cancer-promoting inflammation — have anti-inflammatory therapies come of age?

  2021cites this paper
• Potential biomarkers: differentially expressed proteins of the extrinsic coagulation pathway in plasma samples from patients with depression

  2021cites this paper
• Secondary Mania induced by TNF‐α inhibitors: A systematic review

  2021cites this paper
• Breast Cancer Rehabilitation

  2020cites this paper
• 1-Methylnicotinamide is an immune regulatory metabolite in human ovarian cancer

  2020cites this paper
• Age-related cytokine effects on cancer-related fatigue and quality of life in acute myeloid leukemia.

  2020cites this paper
• Inflammatory biomarkers and patient-reported outcomes in acute myeloid leukemia: Refocusing on older adults.

  2020cites this paper
• Unipolar depression

  2020cites this paper
• Cachexia, a Systemic Disease beyond Muscle Atrophy

  2020cites this paper
• Therapeutic strategies against cancer cachexia

  2019cites this paper
• Zhengyuan capsule alleviates chemotherapy-related fatigue in nude mice with human lung adenocarcinoma A549 xenografts

  2019cites this paper
• The efficacy and safety of Kyung-Ok-Ko on cancer-related fatigue in lung cancer patients

  2019cites this paper
• The role of neuro‐immune interactions in cancer‐related fatigue: Biobehavioral risk factors and mechanisms

  2019cites this paper
• Inflammation- and angiogenesis-related biomarkers are correlated with cancer-related fatigue in colorectal cancer patients: Results from the ColoCare Cohort

  2019cites this paper
• Nutritional issues in patients with cancer

  2019cites this paper
• Asthenia

  2019cites this paper
• Inflammation- and angiogenesis-related biomarkers are correlated with cancer-related fatigue in colorectal cancer patients: Results from the ColoCare Study.

  2019cites this paper
• Crosstalk Between Inflammation and Glutamate System in Depression: Signaling Pathway and Molecular Biomarkers for Ketamine’s Antidepressant Effect

  2018cites this paper
• The PD-L 1-and IL 6-mediated dampening of the IL 27 / STAT 1 anticancer responses are prevented by α-PD-L 1 or α-IL 6 antibodies

  2018cites this paper
• Zweiter österreichischer Konsensus zur sicheren Anwendung von anti-TNF-α-Antikörpern bei chronisch-entzündlichen Darmerkrankungen

  2018cites this paper
• SIRS, CARS and MARS in relationship to cancer cachexia and its clinical implications

  2018cites this paper
• Pharmacologic interventions for fatigue in cancer and transplantation: a meta-analysis.

  2018cites this paper
• [Pain and fatigue - a systematic review].

  2018cites this paper
• Exercise Therapy and Fatigue Management

  2018cites this paper
• Molecular therapeutic strategies targeting pancreatic cancer induced cachexia

  2018cites this paper
• Emerging role of extracellular vesicles in mediating cancer cachexia.

  2018cites this paper
• The PD‐L1‐ and IL6‐mediated dampening of the IL27/STAT1 anticancer responses are prevented by α‐PD‐L1 or α‐IL6 antibodies

  2018cites this paper
• Gut microbiota‐immune‐brain interactions in chemotherapy‐associated behavioral comorbidities

  2018cites this paper
• Inflammation and fatigue in early, untreated Parkinson's Disease

  2018cites this paper
• Neuroimmunology of Behavioral Comorbidities Associated With Cancer and Cancer Treatments

  2018cites this paper
• Rôle de médiateurs de l'inflammation dans l'altération de la fonction musculaire : étude des effets du sepsis et de la chimiothérapie sur un modèle murin

  2017cites this paper
• How and why systemic inflammation worsens quality of life in patients with advanced cancer

  2017cites this paper
• A Practical Approach to Fatigue Management in Colorectal Cancer

  2017cites this paper
• Novel targeted therapies for cancer cachexia.

  2017cites this paper
• Depression as a systemic disease

  2017cites this paper
• Association of Inflammatory Cytokines With the Symptom Cluster of Pain, Fatigue, Depression, and Sleep Disturbance in Chinese Patients With Cancer.

  2017cites this paper
• Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry)

  2017cites this paper
• Fatigue among patients with brain tumors.

  2016cites this paper
• Understanding cachexia as a cancer metabolism syndrome

  2016cites this paper
• The Depressed Frail Phenotype: The Clinical Manifestation of Increased Biological Aging.

  2016cites this paper
• Interferon-alpha-induced inflammation is associated with reduced glucocorticoid negative feedback sensitivity and depression in patients with hepatitis C virus.

  2016cites this paper
• The Role of Dopamine in Inflammation-Associated Depression: Mechanisms and Therapeutic Implications.

  2016cites this paper
• Mast cells' involvement in inflammation pathways linked to depression: evidence in mastocytosis

  2016cites this paper
• Conceptual convergence: increased inflammation is associated with increased basal ganglia glutamate in patients with major depression

  2016cites this paper
• Cancer cachexia—when proteasomal inhibition is not enough

  2016cites this paper
• Impaired regeneration: A role for the muscle microenvironment in cancer cachexia.

  2016cites this paper
• Role of methylphenidate in the treatment of fatigue in advanced pancreatic cancer population

  2016cites this paper
• Cancer cachexia update in head and neck cancer: Pathophysiology and treatment

  2015cites this paper
• Fatigue in immune thrombocytopenia

  2015cites this paper
• Teràpia multimodal per al tractament de la caquèxia cancerosa

  2015cites this paper
• Pharmacological treatments for fatigue associated with palliative care.

  2015cites this paper
• Inflammation: depression fans the flames and feasts on the heat.

  2015cites this paper
• Response to peripheral immune stimulation within the brain: magnetic resonance imaging perspective of treatment success

  2015cites this paper
• Cancer-related and treatment-related fatigue.

  2015cites this paper
• The biology of cancer-related fatigue: a review of the literature

  2015cites this paper
• Chemobrain: a critical review and causal hypothesis of link between cytokines and epigenetic reprogramming associated with chemotherapy.

  2015cites this paper
• Sick and Tired: Mood, Fatigue, and Inflammation in Cancer

  2015cites this paper
• The effect of thalidomide on cachexia in upper gastrointestinal cancer

  2015cites this paper
• Cancer cachexia, mechanism and treatment.

  2015cites this paper
• Symptoms: Fatigue and Cognitive Dysfunction.

  2015cites this paper
• of Cachexia T Cells in the Control + A Novel Role for CD4

  2014cites this paper
• Putting evidence into practice: an update of evidence-based interventions for cancer-related fatigue during and following treatment.

  2014cites this paper
• Cancer-related fatigue—mechanisms, risk factors, and treatments

  2014cites this paper
• From stress to inflammation and major depressive disorder: a social signal transduction theory of depression.

  2014cites this paper
• Neuropsychological features of adult mastocytosis.

  2014cites this paper
• The biology of depression in cancer and the relationship between depression and cancer progression

  2014cites this paper
• The role of depression and neuroimmune axis in the prognosis of cancer patients.

  2014cites this paper
• Recent Developments in Treatment of Cachexia

  2014cites this paper
• Latest developments in cachexia drug discovery: clinical trials

  2013cites this paper
• The systemic inflammatory response and its relationship to pain and other symptoms in advanced cancer.

  2013cites this paper
• Aiming for a better understanding and management of cancer-related fatigue.

  2013cites this paper
• Transcriptional signatures related to glucose and lipid metabolism predict treatment response to the tumor necrosis factor antagonist infliximab in patients with treatment-resistant depression.

  2013cites this paper
• Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications.

  2013cites this paper
• Malaise, melancholia and madness: the evolutionary legacy of an inflammatory bias.

  2013cites this paper
• Combined Effects of Capsaicin and HA14-1 in Inducing Apoptosis in Melanoma Cells

  2013cites this paper
• Tyrosine metabolism during interferon-alpha administration: association with fatigue and CSF dopamine concentrations.

  2013cites this paper
• Correlation between cytokine levels and changes in fatigue and quality of life in patients with acute myeloid leukemia.

  2013cites this paper
• Invalidation du gène de la myostatine dans un modèle murin de cachexie associée au cancer : implication dans la régulation de la masse musculaire

  2013cites this paper
• Predictors of depression in breast cancer patients treated with radiation: Role of prior chemotherapy and nuclear factor kappa B

  2013cites this paper
• A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers.

  2013cites this paper
• Cancer-related fatigue in the elderly

  2013cites this paper